Medication info
Silica Capsule 75mg (Pregabalin)

Silica Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder.
Packaging
30 capsules/bottle, 100 capsules/bottle, 300 capsules/bottle
Approval status
Active

MFDS item code 201205826 · Approved 2012.06.22 · Insurance code 644003220

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of epilepsy (partial-onset seizures); treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25 (mg), maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to an additional dose administered as a single dose. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of epilepsy (partial-onset seizures); treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary generalization
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in epilepsy patients and is effective in both cases with or without secondary generalization. Additionally, it helps alleviate the symptoms of fibromyalgia. In summary, it is used for the treatment of neuropathic pain, partial seizures in epilepsy, and fibromyalgia.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25 (mg), maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to an additional dose administered as a single dose. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, as well as mental health issues such as depression. Patients and caregivers should inform healthcare providers immediately if such symptoms occur. This medication should not be administered to patients with allergies to its components or certain genetic diseases. Diabetic patients may experience weight gain that could affect blood sugar control, which may require adjustments to the dosage of blood sugar medications. If signs of allergic reactions such as angioedema occur, discontinue the medication immediately, paying attention to symptoms of swelling around the face or mouth. Elderly patients should be cautious with the use of this medication due to a higher risk of dizziness and drowsiness, which may increase the risk of falls, especially during the initial days of therapy until they get accustomed to the symptoms. Transient blurred vision or changes in vision may occur, and if such symptoms arise, the patient should consult with a healthcare provider. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headaches, and anxiety; therefore, the dose should be reduced gradually according to a physician's instructions. Patients with a history of substance misuse should be monitored closely for signs of misuse while on this medication. Patients with impaired kidney function may require dose adjustments for this medication. Patients with heart disease should use this medication with caution as it may worsen symptoms of congestive heart failure. Taking this medication with opioid analgesics can significantly increase the risk of central nervous system depression, leading to serious side effects such as respiratory difficulties, and vigilance is necessary. During early pregnancy, this medication may pose a risk of congenital malformations to the fetus, and pregnant women are advised against using it. Women of childbearing age should employ effective contraceptive methods. Lactating women should consult a healthcare provider regarding the potential transfer of this medication into breast milk, which could affect the baby; therefore, nursing should be avoided during treatment or discussed with a professional. This medication may cause dizziness and drowsiness, so caution should be exercised when driving or operating dangerous machinery until symptoms have been confirmed. In case of overdose, symptoms may include confusion, drowsiness, depression, seizures, and treatment such as hemodialysis may be required. Keep this medication out of reach of children, and do not transfer it to another container. If the patient experiences severe rashes, red spots, blisters on the skin while taking this medication, they should stop taking it immediately and consult a healthcare provider.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper respiratory swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, sadness, suicidal ideation, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, impaired respiratory function, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux, decreased oral sensation, ascites, dysphagia, pancreatitis, sweating, papular rash, hives, cold sweat, muscle cramps, joint pain, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urinary dysfunction, urinary incontinence, decreased urine output, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, sensory changes, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased blood creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased potassium levels, weight loss, increased serum creatinine, decreased white blood cell count, rhinitis, neutropenia, increased appetite, appetite loss, hypoglycemia, confusion, sense of direction impairment, irritability, a sense of relief, decreased libido, depersonalization, hypersensitivity, anxiety, mood swings, emotional lability, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, loss of impulse control, apathy, ataxia, abnormal motor coordination, balance disorders, amnesia, attention disorders, memory disorders, tremors, speech disorders, sensory abnormalities, sensory loss, sedation, hypersomnia, cognitive impairments, nystagmus, language disorders, myoclonus, reflex reduction, motor abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, action tremors, syncope, delirium, motor retardation syndrome, olfactory abnormalities, taste loss, writing disability, diplopia, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, hypersensitivity, allergic reactions, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, apathy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confused state, agitation, restlessness, worsening of spasms, shock, anaphylaxis-like symptoms, skin and mucous membrane syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, avoid storing it in excessively hot or cold conditions, and it is best kept at room temperature, between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder.

Package unit

30 capsules/bottle, 100 capsules/bottle, 300 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.